FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Table 1 Demographic characteristics

AC-AD-002 demography	n = 26
Age (years), mean (SD)	67.1 (8.1)
Education level (years), mean (SD)	12.0 (3.7)
Sex
Male	16 (62%)
Female	10 (38%)
Ethnic origin
Caucasian	26 (100%)
MMSE score (before treatment start), mean (SD)	20.7 (4.1)
Modified Hachinski score (before treatment start), mean (SD)	1.0 (0.9)
GDS (before treatment start), mean (SD)	1.3 (1.3)
ApoE status
Carrier	16 (62%)
Non-carrier	10 (38%)
Smoking habit
Smoker	1 (3.8%)
Non-smoker	25 (96.2%)
Medication status
Receiving standard AD medication	24 (92.3%)
Not receiving standard AD medication	2 (7.7%)

Abbreviations: AD Alzheimer’s disease, GDS Geriatric Depression Scale, MMSE Mini Mental State Examination
Data are mean (SD) or number (%). Values labelled as “before treatment start” were recorded at the start of the preceding study and not re-recorded at this study’s screening

ISSN: 1758-9193